

Clover Biopharma to commercialise quadrivalent seasonal influenza vaccine in China

22 February 2023 | News

Partnership with Adimmune adds a second commercial-stage product to Clover's respiratory virus vaccine portfolio



Clover Biopharmaceuticals has entered into an exclusive agreement with Adimmune Corporation for Clover to distribute AdimFlu-S (QIS) in mainland China, the only imported quadrivalent seasonal influenza vaccine which is approved.

AdimFlu-S (QIS) is a quadrivalent split inactivated vaccine for prevention of influenza. The quadrivalent vaccine contains hemagglutinin from four influenza virus strains (two A and two B), which increases its chances of achieving high vaccine effectiveness regardless of which influenza B strain becomes seasonally prevalent relative to trivalent options. AdimFlu-S (QIS) was approved by the China National Medical Products Administration in January 2022 for individuals aged three years and older.

In the near term with commercial launch in H2 2023, Clover will be responsible for the distribution of AdimFlu-S (QIS) throughout mainland China, where the vaccine is already approved and where Clover can leverage its existing commercial infrastructure and growing sales organisation.

The agreement also grants Clover rights to commercialise AdimFlu-S (QIS) in Bangladesh, Brazil and the Philippines, contingent on regulatory approvals, and to potentially collaborate with Adimmune on the development of additional vaccine candidates including next-generation influenza vaccines. Adimmune will manufacture AdimFlu-S (QIS) at its manufacturing facility in China.

The partnership with Adimmune follows the launch of Clover's COVID-19 vaccine, a recombinant SARS-CoV-2 subunit vaccine, in mainland China.